Delivery Order SPE2DR25D6037-SPE2DR26FXK7G
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, valued at $12,474.24 under a firm fixed-price contract. The award was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-set-aside, competitively awarded contract. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order valued at $15,172.51 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials. This firm fixed-price contract, awarded on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this order. The delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $41,605.34 delivery order to AmerisourceBergen Drug Corp for the supply of 100 mg vials of Activase, a thrombolytic medication used in acute medical emergencies. The contract, which became effective on September 15, 2025, with completion targeted for September 16, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at...
- The Defense Logistics Agency awarded a delivery order valued at $22,365.75 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed price contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procurement with no set-aside designation. Performance will take place at...
- The Defense Logistics Agency awarded a $14,839.85 delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, with an ultimate completion date of June 9, 2025. This firm fixed price contract represents a non-set-aside competitive award issued on June 6, 2025, with performance to be fulfilled at the vendor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills...
- The Defense Logistics Agency awarded a $18,607.87 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Activase, a thrombolytic medication used in acute medical emergencies. This competitive award, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $3,261.51 delivery order to AmerisourceBergen Drug Corp for Activase 50 mg vials with a completion date of December 2, 2025. This is a firm fixed price, non-set-aside contract with no preferential consideration applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The delivery order will be fulfilled...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,875.45 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed-price contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive, non-set-aside award. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50mg injectable medication, valued at $13,468.70 with a firm fixed price structure. The award was issued on December 18, 2025, with an ultimate completion date of January 16, 2026. This non-set-aside contract represents a competitive award to the pharmaceutical distributor, which maintains its corporate office in Conshohocken, Pennsylvania, the designated place of performance....
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials valued at $3,351.48. This contract was executed on August 21, 2025, with an ultimate completion date of August 22, 2025, and utilizes firm fixed-price pricing with no set-aside designation. The award was made competitively to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company is headquartered. This...
- SPE2DR25D6037Indefinite Delivery Contract
- SPE2DR25D6037-SPE2DR26FXK7GDelivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $12,310.91 by the Defense Logistics Agency (DLA) for the supply of Activase 100 mg vials, a thrombolytic medication used in emergency medical treatment. The contract is non-competitive and carries a firm fixed price structure, with an ultimate completion date of December 18, 2025. The award was issued on December 17, 2025, and the place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supports military and veteran healthcare systems through the DLA's Medical Supply Chain. The company maintains an extensive portfolio of pharmaceutical deliveries across multiple therapeutic domains and has demonstrated capability to fulfill federal procurement requirements through both competitive and non-competitive awards. This particular delivery order for Activase supports the DLA's mission to supply essential medications to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The firm fixed pricing and rapid turnaround reflect the standardized procurement processes typical of delivery orders issued under established pharmaceutical prime vendor contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 12/16/25 |